Esperion Therapeutis.Inc. buy HC Wainwright
Summary
This prediction is currently active. With a performance of -1.47%, the BUY prediction for Esperion Therapeutis.Inc. by HC_Wainwright is down slightly. This prediction currently runs until 12.08.25. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | -1.47% |
iShares Core DAX® | 2.722% |
iShares Nasdaq 100 | 4.546% |
iShares Nikkei 225® | 6.353% |
iShares S&P 500 | 3.194% |
Comments by HC_Wainwright for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by HC_Wainwright for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
28.06.24
28.06.25
17:37
Esperion Therapeutis.Inc.
21.05.24
21.05.25
17:37
Esperion Therapeutis.Inc.
08.05.24
08.05.25
17:37
Esperion Therapeutis.Inc.
25.03.24
25.03.25
17:37
Esperion Therapeutis.Inc.
28.02.24
28.02.25
17:37
Esperion Therapeutis.Inc.
13.11.23
13.11.24
17:37
Esperion Therapeutis.Inc.
28.08.23
28.08.24
17:37
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24